Clinical Trials Browser

Phase 2 × Has results × Prostatic Neoplasms, Castration-Resistant × Clear all

Prostatic Neoplasms, Castration-Resistant

NCT05551117 2026-02-09

Tamarack

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT05169684 2025-06-10

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Phase 2 Terminated

10 enrolled 15 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT03248570 2024-11-20

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Phase 2 Completed

26 enrolled 18 charts

Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT04157088 2023-08-04

DaroAcT

Phase 2 Terminated

30 enrolled 25 charts

Genitourinary

Prostatic Neoplasms, Castration-Resistant

Clinical Trials

QUEST

Tamarack

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

DaroAcT